The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in pharma: oncolytic viral proteins. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
Oncolytic viral proteins is a key innovation area in immuno-oncology
Oncolytic viruses (OVs) work by two main mechanisms: direct lysis of virus-infected cancer cells and release of tumour antigens as viral bursts. OVs can be attenuated natural viruses or recombinant viruses. A major strategy for OV development is genetic manipulation to weaken virus pathogenicity, enhance target selectivity, reduce adverse reactions, and/or insert exogenous therapeutic genes into the virus genome.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 315+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of oncolytic viral proteins.
Key players in oncolytic viral proteins – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to oncolytic viral proteins
Source: GlobalData Patent Analytics
Akamis Bio, formerly PsiOxus Therapeutics, is one of the leading patent filers in oncolytic viral proteins. It develops and discovers therapies for the treatment of cancer and other related diseases. The company utilises T-SIGn, a tumour-specific immuno gene platform, to develop gene therapies for primary and metastatic solid tumours. Its platform has capabilities to be used in combination with CAR-T and other cell therapies to overcome poor immune cell infiltration, immunosuppressive properties of tumour microenvironment, and systematic toxicity issues. The company has an operational presence in the US and the UK (headquartered in Abingdon, Oxfordshire, UK). Compagnie Merieux Alliance and Advaxis are the other key patent filers of oncolytic viral proteins.
In terms of application diversity, Kolon Life Science is the top company, followed by Genemedicine and Circio.
By means of geographic reach, Vascular Biogenics holds the top position. Aura Biosciences and Johnson & Johnson are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-oncology (IO).
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
